Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Time Lucky? Sun’s Ampyra Generic Appears On Course To Indian Debut

Executive Summary

Amid all the heat around the patents for Acorda Therapeutics’ multiple sclerosis therapy Ampyra (dalfampridine) in the US, Sun Pharma appears to have received a key approval for its generic version of the product in India setting the stage for a potential launch in the country.

Advertisement

Related Content

Acorda Investor Scopia Seeks Big Return From Sale Of The Company
India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel